1.Lee, JY, Bowden, DS. Rubella virus replication and links to teratogenicity. Clinical Microbiology Reviews 2000; 13: 571–587.
2.Department of Health. Immunisation against Infectious Diseases. London: The Stationery Office, 2006, chapter 28, pp. 543–544.
3.Bosma, TJ et al. Use of PCR for prenatal and postnatal diagnosis of congenital rubella. Journal of Clinical Microbiology 1995; 33: 2881–2887.
4.Cooray, S, Jin, L, Best, JM. The involvement of survival signalling pathways in rubella-virus induced apoptosis. Virology Journal 2005; 2: 1.
5.Banatvala, JE, Brown, DWG. Rubella seminar. Lancet 2004; 363: 1127–1137.
6.Preblud, SR, et al. Rubella vaccination in the United States: a ten-year review. Epidemiologic Reviews 1980; 2: 171–194.
7.Tookey, PA, Peckham, CS. Surveillance of congenital rubella in Great Britain, 1971–96. British Medical Journal (Clinical Research Edition) 1999; 318: 769–770.
8.Tookey, P. Rubella in England, Scotland and Wales. Eurosurveillance: European Communicable Disease Bulletin 2004; 9: 21–23.
9.Miller, E, et al. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Communicable Disease Report. CDR Review 1997; 7: R26–32.
15.Cutts, FT, et al. Guidelines for surveillance of congenital rubella syndrome and rubella, 1999. WHO/V&B/99.22. Geneva: World Health Organisation.
16.Dimech, W, et al. Evaluation of eight anti-rubella virus immunoglobulin g immunoassays that report results in international units per millilitre. Journal of Clinical Microbiology 2008; 46: 1955–1960.
17.Tischer, A, et al. Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia. Epidemiology and Infection 2007; 135, 787–797.
18.Skendzel, LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology 1996; 106: 170–174.
19.Bland, M. An Introduction to Medical Statistics, 2nd edn. USA: Oxford Medical Publications, 1996, pp. 225–229, 238–241.
20.Campbell, M. Chi-squared test for linear trend – what's that? Midwifery 2005; 21: 127–130.
21.Cwm Taf Health Board. April 2010 Antenatal screening Wales balanced scorecard report, June 2010.
22.Vyse, AJ, et al. Evolution of surveillance of measles, mumps and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiologic Reviews 2002; 24: 125–136.
23.Yung, C, Skidmore, S, Lord, S. Postpartum MMR immunization uptake in non-immune women. British Journal of Midwifery 2008; 16: 288–291.
25.Gibbons, B. Minister for Health and Social Services, update on MMR Catch-Up Campaign, 2007; HSS (2)-03-07, p. 10. Wales: Welsh Assembly Government.
26.Kakoulidou, M, et al. Serum levels of rubella-specific antibodies in Swedish women following three decades of vaccination programmes. Vaccine 2010; 28: 1002–1007.
27.O'Shea, S, Best, JM, Banatvala, JE. Viraemia, virus excretion, and antibody responses after challenge in volunteers with low levels of antibody to rubella virus. Journal of Infectious Diseases 1983; 148: 639–647.
28.Bonanni, P, et al. Progress in Italy in control and elimination of measles and congenital rubella. Vaccine 2007; 25: 3105–3110.
29.Gioula, G, et al. Seroepidemiology of rubella in northern Greece. European Journal of Clinical Microbiology & Infectious Diseases: Official Publication of the European Society of Clinical Microbiology 2004; 23: 631–633.
32.Mehta, NM, Thomas, RM. Antenatal screening for rubella-infection or immunity? British Medical Journal (Clinical Research Edition) 2002; 325: 90–91.
35.Tookey, PA, Cortina-Borja, M, Peckham, CS. Rubella susceptibility among pregnant women in north London, 1996–1999. Journal of Public Health Medicine 2002; 24: 211–216.
36.Thomas, RM, Mehta, NM. Cases of congenital rubella may be the tip of the iceberg. British Medical Journal (Clinical Research Edition) 2002; 325: 596.